How different PrEP products can improve HIV prevention for young women in Kenya
Official title: Effectiveness of PrEP product choice on HIV prevention coverage among young women in Kenya seeking reproductive health services
Funded at University of Alabama at Birmingham · NIH-10929488 · Data updated 2026-11-12
This study is looking at how well different HIV prevention methods, like special rings and injections, work for young women in Kenya, and it aims to make it easier for them to use these options by improving support from healthcare providers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | September 14, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $586,022 |
| NIH project number | 5R01MH134681-02 |
| Project ID | NIH-10929488 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are young women aged 15-30 in Kenya who are at high risk for HIV and seeking reproductive health services.
✕Less likely to help
Patients who are not at risk for HIV or those who do not seek reproductive health services may not benefit from this research.
What this research studies
This research investigates the effectiveness of various PrEP products, such as dapivirine-eluting vaginal rings and intramuscular injections, in preventing HIV among young women in Kenya. It aims to understand how these longer-acting options can be integrated into existing reproductive health services to improve adherence and reduce dropout rates. By collaborating with public clinic staff, the study focuses on training providers and developing systems to support the delivery of PrEP. The goal is to enhance access to HIV prevention methods for young women who are at high risk.
Why it matters
Potential benefit: If successful, this research could significantly increase HIV prevention coverage among young women, leading to better health outcomes.
How similar studies have gone: Previous research has shown promise in integrating longer-acting PrEP products into reproductive health services, indicating potential for success in this approach.
Where this research is happening
-
University of Alabama at Birmingham
Birmingham, United States Active
Researchers
- Principal investigator: Heffron, Renee a. — University of Alabama at Birmingham
- Study coordinator: Heffron, Renee a.
Related research
Other NIH-funded projects on the same topics.
-
How choosing PrEP products could improve HIV protection for young women in Kenya
This project looks at which HIV-prevention options young Kenyan women prefer and how choosing a product affects how well they stay protected.
-
Effectiveness of PrEP product choice for HIV prevention among young Kenyan women seeking reproductive health services
A study tests which PrEP options best help young Kenyan women stay protected against HIV when they access reproductive health services.
-
PrEP options for young Kenyan women: improving HIV protection and adherence
This grant tests how different PrEP options for young women in Kenya affect steady HIV protection when they access reproductive health services.
-
PrEP choices to prevent HIV for young Kenyan women seeking reproductive care
This project compares daily PrEP pills, a monthly vaginal ring, and injectable PrEP to find which option helps young women getting reproductive health care in Kenya stay protected from HIV.
-
Choosing the best PrEP option to prevent HIV for young women in Kenya
This project offers young women getting reproductive health care in Kenya a choice between daily pills, monthly vaginal rings, or long‑acting injections to see which options help more people stay protected from HIV.
-
PrEP choices to better protect young women at reproductive health clinics in Kenya
This project compares daily pills, monthly injections, and vaginal rings to help young women visiting reproductive health clinics in Kenya stay protected from HIV.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.